- Home
- VFC vs AXSM Comparison
VFC vs AXSM Comparison
Compare VFC & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFC
- AXSM
- Stock Information
- Founded
- VFC 1899
- AXSM 2012
- Country
- VFC United States
- AXSM United States
- Employees
- VFC 30000
- AXSM N/A
- Industry
- VFC Apparel
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- VFC Consumer Discretionary
- AXSM Health Care
- Exchange
- VFC Nasdaq
- AXSM Nasdaq
- Market Cap
- VFC 4.1B
- AXSM 4.8B
- IPO Year
- VFC N/A
- AXSM 2015
- Fundamental
- Price
- VFC $11.36
- AXSM $106.27
- Analyst Decision
- VFC Hold
- AXSM Strong Buy
- Analyst Count
- VFC 19
- AXSM 15
- Target Price
- VFC $22.16
- AXSM $171.00
- AVG Volume (30 Days)
- VFC 13.4M
- AXSM 884.0K
- Earning Date
- VFC 05-21-2025
- AXSM 05-05-2025
- Dividend Yield
- VFC 3.16%
- AXSM N/A
- EPS Growth
- VFC N/A
- AXSM N/A
- EPS
- VFC N/A
- AXSM N/A
- Revenue
- VFC $10,147,207,000.00
- AXSM $385,693,000.00
- Revenue This Year
- VFC N/A
- AXSM $63.52
- Revenue Next Year
- VFC $1.31
- AXSM $63.32
- P/E Ratio
- VFC N/A
- AXSM N/A
- Revenue Growth
- VFC N/A
- AXSM 42.53
- 52 Week Low
- VFC $9.41
- AXSM $64.11
- 52 Week High
- VFC $29.02
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- VFC 38.22
- AXSM 46.35
- Support Level
- VFC $10.07
- AXSM $103.15
- Resistance Level
- VFC $12.03
- AXSM $106.05
- Average True Range (ATR)
- VFC 1.14
- AXSM 5.05
- MACD
- VFC 0.28
- AXSM 0.95
- Stochastic Oscillator
- VFC 64.83
- AXSM 97.32
About VFC V.F. Corporation
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 11 brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.